Highlights

• Imagion Biosystems shares are up 8.33% at AUD 0.013 during the 7 August 2026 session.

• Imagion Biosystems received US FDA clearance in June for its investigational new drug application covering the planned Phase 2 trial of the MagSense HER2 imaging agent.

• The company has a market capitalisation of approximately AUD 7.02mn in the current intraday snapshot.

• The stock is 13.33% lower over one year, placing today's move in a broader performance context.

Imagion Biosystems Ltd (ASX:IBX) is trading higher during Friday's open session as attention returns to its latest operating and corporate developments. The shares are up 8.33% at AUD 0.013 on 7 August 2026, with turnover of about AUD 74. Imagion Biosystems received US FDA clearance in June for its investigational new drug application covering the planned Phase 2 trial of the MagSense HER2 imaging agent. The current move places the latest update against a one-year performance of 13.33% lower, making execution of the next operational milestones central to the story.

Company Overview

Imagion Biosystems is a clinical-stage medical imaging company developing its MagSense molecular MRI platform using bio-safe magnetic nanoparticles.

Recent Developments

Imagion Biosystems received US FDA clearance in June for its investigational new drug application covering the planned Phase 2 trial of the MagSense HER2 imaging agent. In July, the company extended its collaboration with Siemens Healthineers. Imagion also secured firm commitments for an AUD 3.75mn raising to support the clinical trial and later announced non-dilutive short-term funding.

Financial Snapshot

In the current 7 August 2026 intraday snapshot, IBX shares are trading at AUD 0.013, up 8.33%. Turnover is approximately AUD 74 and market capitalisation is about AUD 7.02mn. Over one year, the stock is 13.33% lower. Because the ASX session remains open, these share-price figures may change before the close. The market move therefore provides short-term context rather than a final daily close.

Sector Context

The company's outlook remains closely tied to execution within the healthcare sector. For smaller ASX companies, project milestones, contract delivery, cash resources and access to funding can have a disproportionate effect on valuation. That makes the quality and timing of the next operational update more important than a single intraday percentage move.

What to Watch

The main points to watch are the next update on fda clearance opens the way for the magsense phase 2 trial, progress against the company's stated operational priorities and any change in funding requirements or cash generation. Further announcements that provide measurable evidence of delivery will help determine whether the current market momentum is supported by underlying progress.

Risks

Imagion Biosystems remains exposed to execution, funding and market risks relevant to its sector. Small-cap shares can also experience sharp price movements when turnover is limited. Recent announcements may improve the development or commercial outlook, but they do not remove the need for continued delivery, adequate capital and favourable operating conditions.